Evidence map›Paper›PMID 34853797›Full record

ArticleMolecular therapy. Methods & clinical development2021

Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells.

Motahareh Arjomandnejad, Katelyn Sylvia, Meghan Blackwood, Thomas Nixon, Qiushi Tang, Manish Muhuri, Alisha M Gruntman, Guangping Gao, Terence R Flotte, Allison M Keeler

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. What's new and what's next for gene therapy in Pompe disease?Expert opinion on biological therapy · 2022
    Pooled it
  2. AAVrh32.33 capsid demonstrates unexpected dermal tropism regardless of immunodominant epitope.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  3. Review
  4. Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. 3-in-oneiScience · 2025
    Article
  12. Article
  13. The curious case of AAV immunology.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  14. Review
  15. Role of FoxP3Human gene therapy · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Motahareh ArjomandnejadHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Katelyn SylviaHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Meghan BlackwoodHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Thomas NixonHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Qiushi TangHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Manish MuhuriHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Alisha M GruntmanHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Guangping GaoHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Terence R FlotteHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Allison M KeelerHorae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
University of Massachusetts Chan Medical School · USTufts University · US

Funding

Vector Immunology CoreP01HL158506 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Terence R. Flotte · 2021 to 2026
$19.5M
Viral Vector CoreP01HL131471 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FLOTTE, TERENCE R. · 2016 to 2020
$11.3M
NHLBI NIH HHS P01 HL131471NHLBI NIH HHS P01 HL158506
6 · The paper itself

Abstract

Immune responses to adeno-associated virus (AAV) capsids limit the therapeutic potential of AAV gene therapy. Herein, we model clinical immune responses by generating AAV capsid-specific chimeric antigen receptor (AAV-CAR) T cells. We then modulate immune responses to AAV capsid with AAV-CAR regulatory T cells (Tregs). AAV-CAR Tregs

Indexed as

AAV gene therapyCAR TregsCAR T regulatory cellschimeric antigen receptor T-regulatory cellsimmune responses to AAVimmune responses to capsidimmune responses to transgeneimmunosuppression

Identifiers

PMID34853797
PMCPMC8605179
OpenAlexW3209047410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.